Prism Health North Texas

Our Research Studies

Print Friendly

research studies

Prism Health North Texas, Inc. participates in research studies, making the medical advances of tomorrow available today.

We are honored to participate in the AIDS Clinical Trials Group, one of the largest HIV clinical trials organizations in the world.

The Research Department is currently enrolling for the following research studies:

A5327: Sofosbuvir Plus Ribavirin for Acute Hepatitis C in HIV-Infected Individuals (SWIFT-C)

A5332 – Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)

A5320 – Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

A5324 – A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

A5350 – Safety, Tolerability and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study

A5353 – A Study to Evaluate Dolutegravir plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-infected Participants

A5329 – Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Subjects with HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy

GS-US-380-1489 – A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/ Tenofovir Alafenamide Versus Abacavir/ Dolutegravir/ Lamivudine in HIV-1 Infected,Antiretroviral Treatment-Naïve Adults

GS-US-380-1490 – A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/ Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/ Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

GS-US-380-1878 – A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/ Tenofovir or Abacavir/ Lamivudine to GS-9883/ Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

GS-US-311-1717 – A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC

If you are interested in participating, please contact us to see if there is a study for which you might qualify. Contact: Lauren Rogers, Director of Clinical Research, 972-807-7370, ext. 4465.

Did you know…

Prism Health North Texas has been participating in research studies since 2002 and is nationally recognized for its work?